How have TLSA shares performed in 2024?

Tiziana Life Sciences' stock was trading at $0.56 on January 1st, 2024. Since then, TLSA shares have increased by 18.9% and is now trading at $0.6660. View the best growth stocks for 2024 here .

When is Tiziana Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our TLSA earnings forecast .

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Pfizer (PFE) , Vaxart (VXRT) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Advanced Micro Devices (AMD) , Moderna (MRNA) , Enterprise Products Partners (EPD) , Novavax (NVAX) , Dynavax Technologies (DVAX) and Gilead Sciences (GILD) .

When did Tiziana Life Sciences IPO?

Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

How do I buy shares of Tiziana Life Sciences?

Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TLSA

Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free TLSA Stock Alerts

$0.67

+0.03 (+4.72%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.64
▼
$0.75
50-Day Range: $0.43
▼
$0.67
52-Week Range: $0.41
▼
$1.27

Volume: 597,661 shs
Average Volume: 95,385 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Tiziana Life Sciences alerts:

Tiziana Life Sciences MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.15) to ($0.13) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.46 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Tiziana Life Sciences.

3.0

Short Interest

Percentage of Shares Shorted
Short Interest Ratio / Days to Cover
Tiziana Life Sciences has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Tiziana Life Sciences has recently decreased by 11.92%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Tiziana Life Sciences does not currently pay a dividend.
Dividend Growth
Tiziana Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TLSA.

2.5

News and Social Media Coverage

News Sentiment
Tiziana Life Sciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Tiziana Life Sciences this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
4 people have added Tiziana Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Tiziana Life Sciences are expected to grow in the coming year, from ($0.15) to ($0.13) per share.
Price to Book Value per Share Ratio
Tiziana Life Sciences has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Tiziana Life Sciences Stock (NASDAQ:TLSA)

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

TLSA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TLSA Stock News Headlines

April 19, 2024 | proactiveinvestors.com

Tiziana Life Sciences' foralumab study highlighted in Neurology Today

April 19, 2024 | globenewswire.com

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

April 20, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

April 18, 2024 | proactiveinvestors.com

Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS

April 18, 2024 | globenewswire.com

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

April 11, 2024 | proactiveinvestors.com

Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference

April 11, 2024 | globenewswire.com

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

April 11, 2024 | americanbankingnews.com

Tiziana Life Sciences (NASDAQ:TLSA) vs. Shiseido (OTCMKTS:SSDOY) Head-To-Head Comparison

April 20, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

March 20, 2024 | seekingalpha.com

TLSA Tiziana Life Sciences Ltd

March 5, 2024 | finance.yahoo.com

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

March 5, 2024 | proactiveinvestors.com

Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's disease

March 5, 2024 | globenewswire.com

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

January 5, 2024 | finance.yahoo.com

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

January 5, 2024 | finance.yahoo.com

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

December 22, 2023 | proactiveinvestors.com

Tiziana Life Sciences starts Phase 2a trial and promises results in 2024

December 19, 2023 | finance.yahoo.com

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

December 4, 2023 | finance.yahoo.com

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

November 30, 2023 | proactiveinvestors.com

Tiziana Life Sciences advances multiple sclerosis research...Tiziana Life Sciences advances multiple sclerosis research program...

November 30, 2023 | finance.yahoo.com

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

November 1, 2023 | finance.yahoo.com

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

October 20, 2023 | finance.yahoo.com

TLSA: Six Month SPMS Results

October 18, 2023 | proactiveinvestors.com

Tiziana Life Sciences: FDA signs off on home-based protocol for MS treatment

October 18, 2023 | finance.yahoo.com

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

October 16, 2023 | proactiveinvestors.com

Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial

October 13, 2023 | finance.yahoo.com

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

October 11, 2023 | finance.yahoo.com

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

See More Headlines

Receive TLSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 4/24/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TLSA
CUSIP: N/A
CIK: 1723069
Web: www.tizianalifesciences.com
Phone: 44-20-7495-2379
Fax: N/A
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 3.51

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: 0.82

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Gabriele Marco Antonio Cerrone M.B.A. (Age 52)
Founder, Executive Chairman & Interim CEO
Comp: $444k
Dr. Andrea Brancale
Scientific Founder
Mr. Richard Clarkson Ph.D.
Scientific Founder
Mr. Andrew Westwell Ph.D.
Scientific Founder
Ms. Keeren Shah (Age 48)
Chief Financial Officer
Dr. Matthew W. Davis M.D.
R.Ph., COO & Chief Medical Officer
Dr. William A. Clementi Ph.D.
Pharm.D., Chief Development Officer
Dr. Napoleone Ferrara M.D. (Age 66)
Member of Scientific Advisory Board

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TLSA Stock Analysis - Frequently Asked Questions

How have TLSA shares performed in 2024?: Tiziana Life Sciences' stock was trading at $0.56 on January 1st, 2024. Since then, TLSA shares have increased by 18.9% and is now trading at $0.6660.
View the best growth stocks for 2024 here.
When is Tiziana Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our TLSA earnings forecast.
What other stocks do shareholders of Tiziana Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Pfizer (PFE), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Moderna (MRNA), Enterprise Products Partners (EPD), Novavax (NVAX), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Tiziana Life Sciences IPO?: Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.
How do I buy shares of Tiziana Life Sciences?: Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TLSA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

Tiziana Life Sciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Earnings and Valuation

Earnings Growth

Price to Book Value per Share Ratio

About Tiziana Life Sciences Stock (NASDAQ:TLSA)

TLSA Stock Price History

TLSA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

TLSA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™